All the news Showing 10 of 30 articles from: Genotype 4Get an RSS feed of these articles Show All news infohep newsEditors' picks from other sources HCV treatment feasible and effective in sub-Saharan Africa Keith Alcorn / 17 April 2018 A 12-week course of sofosbuvir/ledipasvir proved highly effective in a sub-Saharan African setting, results of a study carried out in Rwanda show. The findings were presented on Friday at the ... CHMP Grants Positive Opinion for Shorter Treatment Duration with AbbVie's VIEKIRAX® for Patients with Genotype 4 Chronic Hepatitis C with Compensated Cirrhosis (Child-Pugh A) Manual Items / 26 July 2016 Elbasvir/grazoprevir superior to sofosbuvir and pegylated interferon/ribavirin Michael Carter / 10 May 2016 New research has demonstrated the clear superiority of an oral combination of direct-acting antivirals (DAAs) over a regimen that combines a DAA with pegylated interferon and ribavirin for the treatment of chronic hepatitis ... Ravidasvir plus sofosbuvir demonstrates high cure rate for people with hepatitis C genotype 4 Liz Highleyman / 02 March 2016 Sofosbuvir plus the investigational HCV NS5A inhibitor ravidasvir, with or without ribavirin, cured 95 to 100% of people with hepatitis C virus (HCV) genotype 4, the most common type in Egypt, ... Sofosbuvir/ledipasvir for 6 weeks cures HCV in HIV-positive people with acute HCV if viral load is low Liz Highleyman / 26 February 2016 An interferon- and ribavirin-free regimen of sofosbuvir/ledipasvir (Harvoni) taken for just 6 weeks was enough to cure hepatitis C in HIV-positive people with recent hepatitis C virus (HCV) infection if their HCV viral ... Daclatasvir approved for use in HIV/HCV co-infection, decompensated cirrhosis and post-transplant in the EU Keith Alcorn / 03 February 2016 The hepatitis C direct-acting antiviral daclatasvir (Daklinza) has received European Union marketing approval for use in three new populations of people with genotype 1, 3 or 4 hepatitis C infection. The NS5A inhibitor ... New Merck combination pill Zepatier approved for hepatitis C treatment in the United States Keith Alcorn / 01 February 2016 Merck has received a US license for its direct-acting antiviral combination of grazoprevir and elbasvir, to be marketed as Zepatier. The combination of grazoprevir (an HCV protease inhibitor) and elbasvir (an NS5A inhibitor) ... Merck Throws a Wrench in Drug Pricing Bloomberg / 01 February 2016 Zepatier for hepatitis C approved in Canada CATIE / 01 February 2016 Merck Receives FDA Approval of ZEPATIER™ (elbasvir and grazoprevir) for the Treatment of Chronic Hepatitis C Virus Genotype 1 or 4 Infection in Adults Merck press release / 29 January 2016 ← First123Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive